Cargando…
Dose distribution changes with shielding disc misalignments and wrong orientations in breast IOERT: a Monte Carlo – GEANT4 and experimental study
One of the most relevant risks in breast intraoperative electron radiotherapy (IOERT) is the incorrect positioning of the shielding disc. If such a setup error occurs, the treatment zone could receive a nonuniform dose delivery, and a considerable part of the electron beam could hit — and irradiate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718242/ https://www.ncbi.nlm.nih.gov/pubmed/22955646 http://dx.doi.org/10.1120/jacmp.v13i5.3817 |
Sumario: | One of the most relevant risks in breast intraoperative electron radiotherapy (IOERT) is the incorrect positioning of the shielding disc. If such a setup error occurs, the treatment zone could receive a nonuniform dose delivery, and a considerable part of the electron beam could hit — and irradiate — the patient's healthy tissue. However misalignment and tilt angle of the shielding disc can be evaluated, but it is not possible to measure the corresponding in vivo dose distribution. This led us to develop a simulation using the Geant4 Monte Carlo toolkit to study the effects of disc configuration on dose distribution. Some parameters were investigated: the shielding factor (SF), the radiation back scattering factor (BSF), the volume–dose histogram in the treatment zone, and the maximum leakage dose (MLD) in normal tissue. A lateral shift of the disc (in the plane perpendicular to the beam axis) causes a decrease in SF (from 4% for a misalignment of 5 mm to 40% for a misalignment of 40 mm), but no relevant dose variations were found for a tilt angle until 10°. In the same uncorrected disc positions, the BSF shows no significant change. MLD rises to 3.45 Gy for a 14 mm misalignment and 4.60 Gy for 30° tilt angle when the prescribed dose is 21 Gy. The simulation results are compared with the experimental ones, and allow an a posteriori estimation of the dose distribution in the breast target and underlying healthy tissue. This information could help the surgical team choose a more correct clinical setup, and assist in quantifying the degree of success or failure of an IOERT breast treatment. PACS number: 87.53.Jw, 87.55.dk, 87.55.Gh, 87.55.K‐, 87.55.N‐ |
---|